HiTT on tour
health & around thoughts, on the fly & on the flight
Two companies supported by HiTT get outstanding reward.
HiTT celebrates that Barcelona Activa recognizes Qbeast with an award for the best project of high technological impact and Hospital Vall d’Hebron obtains more than 1M€ benefit from the exploitation of a patent license.
read more
Perspectives to mitigate payer uncertainty in health technology assessment of novel oncology drugs
Oriol Sola Morales has collaborated in the creation of an article about reimbursement decisions on new oncology drugs. You can access to the entire article in this link.
read more
Big Data analytical tools project
Health Innovation Technology Transfer (HITT) is working on the development of an European project in Big Data tools. This project tries to understand the needs of the professionals that use Big Data tools in its analytical procedures.
read more
New acquisition cost of Repatha
Today we learn that Amgen is lowering the acquisition cost of Repatha by 60% in the US.
read more
Gene therapy: Will it deliver its commercial promise?
On April 10th 2018, Goldman Sachs published “The Genome Revolution” report on gene therapy, in which its analyst posed the thought-provoking question: “is curing patients a sustainable business model?”
read more
Drugs in the graveyard increase costs
This week we learned that Merck & Co. was ending the Phase III APECS study of Verubecestat (formerly known as MK-8931) for the treatment of prodromal Alzheimer Disease. Yet another drug in AD graveyard!!
read more